A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

First NK Cell Therapy Approval Expected By 2028 Says Kuick Research In Its New Research Study On Global NK Cell Therapy ...

NK cell immunotherapy has not yet reached that stage. “The natural killer cell approach in terms of cancer immunotherapy is newer, and rapidly gaining recognition,” says Hans-Gustaf Ljunggren ...

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) is navigating a critical juncture in its journey to develop innovative natural killer (NK) cell therapies for autoimmune diseases and cancers.

One of the lead candidates in Sanofi natural killer (NK) cell engager alliance with Innate Pharma has shown encouraging and durable efficacy in various haematological cancers, according to a phase ...

NKGen Biotech's CEO will present Phase 1 clinical trial results for NK cell therapy in Alzheimer's at AD/PD™ 2025. NKGen Biotech, Inc. announced that its CEO, Dr. Paul Y. Song, will present at ...

About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is ...

Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section on Artivabio.com . A webcast replay will be made available following the ...